NasdaqGM - Nasdaq Real Time Price USD

Keen Vision Acquisition Corporation (KVACW)

0.0501
-0.0149
(-22.92%)
At close: May 12 at 4:00:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for KVACW

Recent News: KVACW

View More
Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress

Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress
GlobeNewswire 22 hours ago
Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit

Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit
GlobeNewswire last month
Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction

Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction
GlobeNewswire last month
Medera Completes Patient Dosing for Heart Failure Treatment

Medera Completes Patient Dosing for Heart Failure Treatment
Exec Edge 2 months ago
Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction

Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction
GlobeNewswire 2 months ago
Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht
GlobeNewswire 2 months ago
Medera, Inc. to Participate in Two Upcoming Investor Conferences

Medera, Inc. to Participate in Two Upcoming Investor Conferences
GlobeNewswire 3 months ago
Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening
GlobeNewswire 4 months ago
Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing
GlobeNewswire 4 months ago
Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology
PR Newswire 6 months ago
Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction
PR Newswire 6 months ago
View More

Related Tickers

CUBWW Lionheart Holdings
0.1900
0.00%
 
BSIIW
0.5643
+37.63%
 
AEAE AltEnergy Acquisition Corp.
11.61
+0.09%
 
SVII Spring Valley Acquisition Corp. II
11.67
+0.52%
 
MLAC Mountain Lake Acquisition Corp.
10.16
+0.20%
 
SVIIW Spring Valley Acquisition Corp. II
0.1330
+10.83%
 
CCIXW Churchill Capital Corp IX
1.0000
+1.62%
 
GPATW GP-Act III Acquisition Corp.
0.2457
-16.71%
 
CUB Lionheart Holdings
10.36
0.00%
 
DMYY dMY Squared Technology Group, Inc.
14.12
-1.94%